• DOI:10.1136/bmjspcare-2017-001440
Corpus ID: 3318359

Cancer cachexia: rationale for the MENAC (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial

@article{Solheim2018CancerCR,
  title={Cancer cachexia: rationale for the MENAC (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial},
  author={T. Solheim and B. Laird and T. R. Balstad and A. Bye and G. Stene and V. Baracos and F. Strasser and G. Griffiths and M. Maddocks and M. Fallon and S. Kaasa and K. Fearon},
  journal={BMJ Supportive & Palliative Care},
  year={2018},
  volume={8},
  pages={258 - 265}
}

• T. Solheim, B. Laird, +9 authors K. Fearon
• Published 2018
• Medicine
• BMJ Supportive & Palliative Care

Cancer cachexia is a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a major impact on patient physical function, morbidity and mortality. Despite the consequences of cachexia, there is no licensed treatment for cachexia and no accepted standard of care. It has been argued that the multifactorial genesis of cachexia lends itself to therapeutic… Expand

View on BMJ

kclpure.kcl.ac.uk

Save to Library

Create Alert

Cite

Launch Research Feed